News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Erdafitinib prevails in bladder cancer with select FGFRalt
22 Jun 2023
byAudrey Abella
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
22 Jun 2023

SGLT2 inhibitors score big, this time in gout
22 Jun 2023
byElvira Manzano
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
22 Jun 2023






